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Abstract 
Background 
Leptin, a protein hormone produced by adipose tissue, is a known regulator of satiety and is also 
associated with inflammation, cell proliferation and differentiation. Excess adiposity, in cases of 
obesity, is associated with increased leptin levels, an increase in the expression of tumor-
initiating cell (TIC) associated genes, as well as worse outcomes for triple-negative breast cancer 
(TNBC). In this study we characterize the impact of obesity-associated leptin signaling on TIC 
enrichment as well as determine the role of leptin on signaling on obesity-associated 
chemotherapy resistance. 
 
Methods 
The in vitro effects of leptin on TIC enrichment were examined by mammosphere formation 
assay. Met-M-Wnt cells treated with vehicle (sterile H2O) or leptin for 7 days, and the number of 
mammospheres was quantified. Leptin receptor, Lepr, expression in the E-Wnt, Met-M-Wnt, and 
MDA-MB-231 cell lines after leptin treatment was determined by quantitative RT-PCR.  The 
role that leptin signaling has in any significant phenotypic differences between control and DIO 
conditions was investigated using stable knockdown of Lepr in the Met-M-Wnt cells using 
shRNA. Cell viability in E-Wnt, Met-M-Wnt, and MDA-MB-231 cells in response to docetaxel 
was assessed using MTT assays to define chemo-sensitivity. To investigate the effects of in vivo 
leptin signaling on chemotherapy resistance, both E-Wnt cells with Lepr knockdown and 
scrambled shRNA transfected cells (Ewnt-L and Ewnt-S) were transplanted into the mammary 
fat pads of C57BL/6 mice. The mice were randomized to a control (10% kcal from fat) or diet-
induced obesity (DIO, 60% kcal from fat) diet for 15 weeks and were further randomized to 
vehicle (saline) or docetaxel (20 mg/kg/week x 3 doses) treatment groups. Tumor growth rates 
and final tumor volume were determined. 
 
Results 
Increased leptin treatment significantly increased mammosphere formation in Met-M-Wnt cells 
(P<0.05) but not leptin receptor expression in these cells or E-Wnt or MDA-MB-231 cells. 
Stable Lepr shRNA transfection in the Met-M-Wnt cells significantly reduced Lepr expression 
(P<0.001). In the in vivo study, tumor growth rate in EWnt-L, but not EWnt-S tumors, was 
significantly reduced in DIO mice after docetaxel treatment (P<0.05). Growth rate in both 
tumors was significantly decreased with docetaxel treatment in the control mice (P<0.05). 
 
Conclusions 
Leptin signaling may promote TIC enrichment in metastatic claudin-low breast cancer but does 
not upregulate leptin receptor expression in TNBC. Obesity-associated leptin signaling promotes 
docetaxel resistance in a model of basal-like breast cancer. Given these relationships, targeting 
pathways downstream of leptin signaling should be further investigated as a potential treatment 
option for obesity-associated chemotherapy resistance. 
3 
 
Table of Contents  
 
1. Introduction         5 
a. Breast Cancer Prevalence and Significance    5 
b. Impact of Obesity and TNBC      5 
c. Breast Tumor-Initiating Cells and Obesity    6 
d. Leptin and TIC Link       7 
2. Goal and Hypotheses        8 
3. Methods         9 
a. Cell Lines        9 
b. Mammosphere Assays      9 
c. Leptin Effect on Lepr Expression     9   
d. Met-M-Wnt Leptin Receptor Knockdown    10 
e. Characterization of Docetaxel Response    10 
f. Animal Study        10 
g. Statistical Analysis       11 
4. Results         12 
a. Aim 1         12 
i. Mammosphere Assay      12 
ii. Leptin Receptor Expression     13 
iii. shRNA Lepr Knockdowns     16 
iv. Knockdown Twist2 Expression    16 
b. Aim 2         17 
i. Docetaxel Response      17  
ii. E-Wnt Docetaxel Response with DIO Serum  18 
iii. Animal Study       19 
1. Tumor Growth Rate     19 
2. Final Tumor Volume     21 
5. Discussion         22 
6. Conclusion         25 
7. Future Directions        26 
8. Works Cited         27 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acknowledgements 
I would like to thank Dr. Stephen Hursting for the opportunity to conduct the research necessary 
to complete this thesis in a welcoming and productive laboratory. I would also like to thank Dr. 
Laura W. Bowers for her guidance and patience as a mentor because this project would not have 
been possible without her support.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
Introduction  
 
Breast Cancer Prevalence and Significance 
Breast cancer is the most prevalent form of cancer for females and in 2014, there was an 
estimated 3,327,552 women living with breast cancer in the United States. According to the 
National Cancer Institute (NCI) in 2017, an estimated 40,610 deaths were attributed to breast 
cancer [1]. The NCI estimates that one in eight women born in the United States will develop 
breast cancer [1], and millions of breast cancer patients may be adversely impacted by the effects 
of some form of the disease. Furthermore, 15-25% of breast cancers are found to be triple-
negative breast cancer (TNBC) which is a subtype of tumors that tests negative for estrogen 
receptors (ER-), progesterone receptors (PR-), and HER (HER2-) [2]. The highly aggressive 
nature and metastatic properties of TNBC coupled with the few treatment options outside of 
traditional chemotherapy correlates with a higher mortality rate than other subtypes of breast 
cancer [3].  
 
Impacts of Obesity and TNBC 
Obesity is currently a significant global health problem and more than 35% of Americans 
are categorized as obese with a body mass index (BMI) of ≥30 kg/m2 [4, 5]. Obesity is 
associated with greater risk and progression of many diseases, including breast cancer. Excess 
adiposity is correlated with a worse prognosis in all breast cancer subtypes, including TNBC [6, 
7]. The strength of association between poorer overall survival across all breast cancer subtypes 
increases with each successive increase in BMI category [8]. Cytotoxic chemotherapy remains 
the primary treatment for TNBC due to the lack of hormonal molecular targets in these tumors 
[9]. However, several studies have demonstrated that obesity is specifically linked to a worse 
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disease outcome in patients that received neoadjuvant cytotoxic chemotherapy, including taxanes 
and anthracyclines [10]. These findings suggest that obesity may promote resistance to multiple 
types of chemotherapy via a common mechanism. Consequently, it is important that we improve 
our understanding of the mechanism(s) mediating the obesity-chemotherapy resistance link, with 
a particular focus on TNBC, as the treatment options for this highly aggressive breast cancer 
subtype are limited to cytotoxic chemotherapies. 
 
Breast Tumor-Initiating Cells and Obesity 
One factor that is thought to promote chemotherapy resistance is an enrichment in the 
tumor-initiating cell (TIC) population. TICs are a subpopulation of cancer cells located within a 
tumor with stem cell-like properties, including the capacity for self-renewal and multipotent 
differentiation. According to the TIC model, these cells are the primary drivers of chemotherapy 
resistance, and this hypothesis has been supported in breast cancer patients by associations 
between TIC enrichment and poor patient prognosis [11]. Therefore, an improved understanding 
of how obesity-induced TIC enrichment affects chemotherapy response in obese TNBC patients 
may inform the development of a more effective treatment regimen for these patients. 
Dunlap et al. [12] previously demonstrated that diet-induced obesity (DIO) increases the 
expression of TIC-related genes in TNBC along with an upregulation of markers of epithelial-to-
mesenchymal transition (EMT), a key process that is closely linked with TIC enrichment and 
metastasis. In a recent study, our laboratory used a transgenic mouse model of basal-like breast 
cancer, the most common form of TNBC, to examine the impact of DIO on TIC enrichment. 
DIO doubled tumor incidence, increased tumor growth rate by 2.5 times (P<0.05), and increased 
TIC-associated gene expression [20]. 
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Leptin and TIC Link 
Leptin is a hormone produced by adipocytes that is primarily known as a regulator of 
satiety. However, it is also produced by breast cancer cells and regulates inflammation, cell 
differentiation, and proliferation. Leptin therefore may mediate obesity-induced breast cancer 
progression through multiple mechanisms [13]. Excess adiposity in obese patients is correlated 
with increased leptin levels. Obesity has also been linked to a worse prognosis for all subtypes of 
breast cancer, including the highly aggressive TNBC subtype. Leptin signaling may contribute to 
this link, as obesity has been shown to promote tumor growth and TIC enrichment in 
transplanted tumors, but only when leptin signaling is present [14]. Increased levels of systemic 
leptin and tumor leptin and leptin receptor expression have been associated with worse breast 
cancer prognosis [15-18]. It has been shown that silencing the leptin receptor in MDA-MB-231, 
a human breast cancer cell line, reduced the metastatic properties of the tumor cells by exhibiting 
a mesenchymal-to-epithelial transition [19]. Therefore, it is likely that leptin is a key contributor 
to obesity-associated chemotherapy resistance in TNBC via its promotion of TIC enrichment. 
Using in vitro models of basal-like and claudin-low breast cancer along with an 
orthotopic transplant mouse model of basal-like breast cancer, we tested the hypothesis that 
increased leptin signaling mediates obesity-associated TNBC development by promoting TIC 
enrichment. 
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Goal and Hypothesis 
The primary goal of the current study was to determine whether obesity-associated leptin 
signaling contributes to chemotherapy resistance in TNBC via TIC enrichment. This was 
accomplished through two separate specific aims.  
The first aim was to characterize the impact obesity-associated leptin signaling on TIC 
enrichment in TNBC in vitro using two murine (E-Wnt and Met-M-Wnt) and one human (MDA-
MB-231) breast cancer cell line. We hypothesized that obesity-associated leptin signaling will 
enhance markers of TIC enrichment and leptin receptor expression in these cell lines.  
The second aim was to determine the role played by leptin signaling in obesity-associated 
chemotherapy resistance. This aim was addressed via in vitro characterization of the E-Wnt, 
Met-M-Wnt, and MDA-MB-231 cells’ response to docetaxel as well as an animal study 
examining the effects of obesity-associated leptin signaling on E-Wnt cell response to docetaxel. 
The taxane drug docetaxel was used in these studies because it is commonly used to treat breast 
cancer, and obesity has been linked to taxane resistance. We hypothesized, given the known 
relationships between obesity-associated leptin signaling and TIC enrichment as well as TIC 
enrichment and chemoresistance, that silencing the leptin receptor will improve E-Wnt 
mammary tumor response to docetaxel treatment in obese mice.  
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Methods 
Cell Lines 
Two triple-negative mouse mammary tumor cell lines isolated from the MMTV-Wnt-1 mouse 
model, E-Wnt (basal-like) and Met-M-Wnt (metastatic, claudin-low), along with human MDA-
MB-231 (claudin-low) breast cancer cells were used in the in vitro studies. The cell lines were 
maintained in RPMI 1640 media (GIBCO Life Technologies) supplemented with 10% fetal 
bovine serum, 10 mM HEPES buffer, and 2 mM L-glutamine (complete media). All experiments 
were performed on cells maintained at <30 passages and within 10 passages of cell line removal 
from liquid nitrogen storage. 
 
Mammosphere Assays 
Met-M-Wnt cells were plated for mammosphere assays at a density of 1 x 104 cells/well in ultra-
low attachment 6-well plates. Cells were treated with vehicle (sterile H2O) or leptin (100, 200, and 
400 ng/mL) for 7 days. The number of mammospheres was quantified at the end of the treatment 
period using an EVOS FL Auto 2 Cell Imaging System (Invitrogen). 
 
Leptin Effect on E-Wnt, Met-M-Wnt, and MDA-MB-231 Lepr Expression 
The E-Wnt, Met-M-Wnt, and MDA-MB-231 cell lines were treated with either vehicle (sterile 
H2O) or leptin (50, 100, 200, and 400 ng/mL) for 6, 24, or 48 hours. Total RNA was isolated 
from cell lines using TRIzol® Reagent (Sigma-Aldrich) according to manufacturer’s instructions, 
reverse transcribed to cDNA using MultiScribe Reverse Transcriptase (ThermoFisher Scientific), 
assayed using TaqmanTM Gene Expression Assays (Applied Biosystems), and analyzed in 
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triplicate by quantitative RT-PCR on a ViiATM7 RT-PCR (Applied Biosystems) to determine 
relative expression of the leptin receptor.  
 
Met-M-Wnt Leptin Receptor Knockdown 
Lepr shRNA or scrambled shRNA plasmids (Santa Cruz Biotechnologies) were transfected into 
Met-M-Wnt cells using FuGENE 6 (Promega) to generate stable leptin receptor knockdown and 
control Met-M-Wnt cell lines. Total RNA was isolated from cell lines using the process 
described above and quantitative RT-PCR was used to determine relative expression of Lepr. 
Two stably transfected lines (ObR-3 and ObR-8) were selected based on relative expression of 
leptin receptor to the cells transfected with the scrambled plasmid (Con-5). The parental Met-M-
Wnt line used to generate these 3 lines was also utilized for comparison in the in vitro 
experiments.   
 
Characterization of E-Wnt, Met-M-Wnt, MDA-MB-231 Docetaxel Response  
 
Following a 48-hr treatment with vehicle (EtOH) or docetaxel (doses: 50 nM, 100nM, 500 nM, 1 
M, and 2 M), cell viability in E-Wnt, Met-M-Wnt, and MDA-MB-231 cells was assessed using 
MTT assays to define chemo-sensitivity and determine optimal docetaxel dose and treatment time 
for each cell line. 
  
Animal Study 
12-week old female ovariectomized C57BL/6 mice were randomized to a control (10% kcal from 
fat) or diet-induced obesity (DIO, 60% kcal from fat) diet for 15 weeks. All mice were then 
orthotopically injected with E-Wnt cells stably transfected with a scrambled shRNA plasmid 
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(EWnt-S, 9th mammary fat pad) and E-Wnt cells stably transfected with a Lepr shRNA plasmid 
(EWnt-L, 4th mammary fat pad), both generated previously for a prior study [20]. The mice in each 
diet group were further randomized to vehicle (saline) or docetaxel (20 mg/kg/week x 3 doses) 
treatment groups. Each mouse was started on injections when it had at least 1 tumor of 200 mm3. 
Each mouse was euthanized when it had at least 1 tumor of >1.5 cm diameter. Following 
euthanasia, tumor diameters in each of 3 dimensions (D1, D2 and D3) were measured ex vivo with 
digital calipers. The ellipsoid equation was used to determine volume: 1/6(D1 x D2 x D3). 
Growth rate was calculated by subtracting the estimated tumor volume at the start of injections 
(estimated using the 2 dimensions measured at last palpation: 1/6(D1 x D2 x D2), where D2 is 
the smaller dimension) from final tumor volume and dividing this difference by the number of 
days between the first injection and euthanization: (Final tumor volume – Tumor volume at 
injection start)/Number of days 
 
Statistical Analysis 
Animal study data is presented as mean  SD. In vitro data is presented as mean  SEM. 
GraphPad Prism 7 software (GraphPad) was used to perform all statistical tests. One-way 
ANOVA, followed by Tukey’s post hoc test, was used to analyze data from experiments with 
one independent variable. Two-way ANOVA, followed by Tukey’s post hoc test, was used to 
analyze data from experiments with two or more independent variables. P<0.05 was considered 
statistically significant.   
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Results 
Aim 1 
Mammosphere Assay Counts 
The in vitro effect of leptin (100, 200, and 400 ng/mL, final concentrations) on mammary TIC 
enrichment was examined in the mouse triple-negative mammary tumor cell line (Met-M-Wnt) by 
assessing mammosphere formation. Leptin, compared with vehicle, increased Met-M-Wnt cell 
mammosphere formation significantly at 200 ng/mL (P<0.05) and non-significantly at the 400 
ng/mL dose (Figure 1). Our lab previously found that increased leptin dose similarly increased the 
number of mammospheres in murine (E-Wnt) and human (MDA-MB-231) triple-negative 
mammary tumor cell lines. Furthermore, silencing Lepr expression via shRNA in E-Wnt cells 
significantly reduced mammosphere count, which suggests that leptin signaling mediates 
mammosphere formation in this cell line [20]. 
 
 
Figure 1. Met-M-Wnt mammosphere counts following a 7-day treatment with leptin.  
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Leptin Receptor Expression  
 
Leptin treatment did not significantly change leptin receptor expression across all triple-negative 
mammary tumor cell lines assessed: E-Wnt, Met-M-Wnt, and MDA-231 (Figures 2-4). 
 
Figure 2. E-Wnt relative Lepr (ObR) expression following (A) 6 Hour, (B) 24 Hour, and (C) 48 
Hour treatments with leptin.  
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Figure 3. Met-M-Wnt relative Lepr (ObR) expression following (A) 6 Hour, (B) 24 Hour, and 
(C) 48 Hour treatments with leptin. 
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Figure 4. MDA-MB-231 relative Lepr (ObR) expression following (A) 6 Hour, (B) 24 Hour, and 
(C) 48 Hour treatments with leptin. 
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shRNA Lepr Silenced Knockdowns 
Lepr expression was measured in two stably transfected Lepr knockdown Met-M-Wnt lines (ObR3 
and ObR8) relative to Met-M-Wnt cells stably transfected with a scrambled shRNA plasmid 
(Con5). Lepr expression in ObR3 and ObR8 was significantly reduced to 0.118±0.0124 and 
0.406±0.0442, respectively, relative to the Con5 cells (P<0.0001).  
 
 
Figure 5. Met-M-Wnt relative Lepr (ObR) expression following Lepr knockdown by shRNA. 
 
No significant decrease was observed in met-M-Wnt Twist2 expression with Lepr knockdown, 
though it was reduced in ObR3 cells by approximately 50% relative to Con5 (Figure 6). No 
significant differences between Met-M-Wnt clones were noted in expression of other TIC/EMT-
associated genes measured: Akt3, Foxc2, Sox2, and Vim (data not shown). 
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Figure 6. Met-M-Wnt Twist2 expression after Lepr knockdown. 
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Aim 2 
Docetaxel Response  
A significant decrease in cell viability was observed for a 50 nM dose of docetaxel in all cell 
lines assessed. Larger doses of docetaxel do not significantly reduce cell viability further in these 
cells (Figure 7). 
 
Figure 7. (A) E-Wnt (B) MDA-MB-231, and (C) Met-M-Wnt cell response to docetaxel in vitro 
was assessed by MTT assay.  
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E-Wnt Docetaxel Response with DIO Serum 
To examine the association between leptin signaling and docetaxel response in vitro, the E-Wnt 
cell line was exposed to serum from DIO or control mice that was collected as part of a previous 
study [20]. There was a significant difference between the DIO and control serum-treated cells in 
response to docetaxel at both the 50 nM and 500 nM doses (P<0.05; Figure 8). However, since 
DIO serum contains other obesity-associated factors, a causal relationship cannot be established 
between leptin and docetaxel response from this data.   
 
 
Figure 8. E-Wnt Docetaxel response with DIO serum 
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E-Wnt Animal Data 
Our laboratory previously generated leptin receptor knockdown E-Wnt cells using shRNA to 
silence LepR expression. Knockdown for EWnt-L2 was determined to be 0.376 relative to the 
EWnt cells transfected with a scrambled shRNA sequence (EWnt-S) (P<0.001; Figure 9).  
 
Figure 9. Lepr expression in E-Wnt shRNA Lepr knockdown cells 
 
Tumor Growth Rate 
To establish the relationship between leptin signaling and chemotherapy resistance, 1 stably 
transfected Lepr knockdown E-Wnt cell line (EWnt-L2 designated EWnt-L during transplantation) 
and the E-Wnt cell line stably transfected with scrambled plasmid (EWnt-S) were injected into the 
4th and 9th mammary fat pads, respectively, and docetaxel treatment started in each mouse when 1 
tumor 200 mm3. Body weight of the DIO mice was significantly greater than controls during 
weeks 2-14 on diet (data not shown).  
In the DIO mice, docetaxel was ineffective at reducing EWnt-S tumor growth rate. However, there 
was a significant decrease in EWnt-L tumor growth rate in docetaxel treated mice compared to 
vehicle-treated mice (P<0.05; Figure 10A). For mice on the control diet, there was a significant 
difference between vehicle- and docetaxel-treated mice in the growth rate of both tumors, 
indicating that docetaxel was effective for both cell lines in the absence of an obesity-associated 
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increase in systemic leptin (P<0.05; Figure 10B). These findings suggest that leptin signaling 
mediates obesity-induced docetaxel resistance in the E-Wnt cell line.  
 
 
Figure 10. Tumor growth rate in (A) DIO and (B) Control mice following the start of vehicle or 
docetaxel injections. 
  
Final Tumor Volume 
 
In the DIO mice, there was no significant difference in the EWnt-S or EWnt-L final tumor 
volume between vehicle and docetaxel treatment. However, the difference in final EWnt-L tumor 
volume between vehicle versus docetaxel-treated DIO mice approached significance (Figure 
11A). There were no significant differences between the vehicle and docetaxel treatment groups 
in final volume of both tumors in the control mice, though there was decreased final tumor 
volume in the docetaxel mice relative to vehicle mice that approached significance (Figure 11B). 
This lack of significance reflects a large within group variability in final tumor volume.  
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Figure 11. Final Tumor Volume in (A) DIO (B) Control 
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Discussion 
Despite the well-established association between obesity and overall worse outcomes for 
TNBC, the mechanisms that mediate this link are not fully known. These findings suggest that a 
leptin-dependent mechanism(s) could lead to increased tumor growth and chemotherapy 
resistance, possibly via TIC enrichment. Specifically, we report that (a) mammosphere counts 
increased as leptin dose increased for the Met-M-Wnt cell line, (b) leptin exposure does not 
increase leptin receptor expression in two murine triple-negative cell lines (E-Wnt and Met-M-
Wnt) and 1 human line (MDA-MB-231) in vitro, (c) Lepr knockdown in Met-M-Wnt cells resulted 
in no significant differences in TIC-related gene expression, though Twist2 was non-significantly 
decreased, (d) leptin signaling is a key mediator for obesity-associated docetaxel resistance in the 
E-Wnt model of TNBC.  
Chang et al. demonstrated that leptin induces an EMT phenotype, mammosphere 
formation, and Lepr expression in pre-clinical models of normal breast epithelial cells (MCF12A) 
and luminal A breast cancer (MCF7) [21]. Our laboratory previously demonstrated that leptin 
treatment increases mammosphere formation in E-Wnt cells, while mammosphere formation is 
reduced in Lepr silenced E-Wnt cells [20]. Klopp et al. found that mesenchymal TIC, which are 
known to support tumor growth, increases the formation of mammospheres [22]. Therefore, to 
evaluate the in vitro TIC enrichment of leptin, we used a mammosphere assay for the Met-M-Wnt 
cell line treated with leptin. There was a significant increase in mammosphere count with increased 
leptin dose (Figure 1), which may be attributable to TIC-enrichment by leptin. In our results, 
however, leptin did not appear to have a significant effect on Lepr expression in both the basal-
like (E-Wnt) cell line and the claudin-low cell lines (Met-M-Wnt and MDA-MB-231).  
Our laboratory and others have previously found that the growth of transplanted mammary 
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tumors is enhanced in obese db/db mice, which have a significant elevation in systemic leptin due 
to a Lepr gene mutation. However, growth of transplanted mammary tumors is reduced in the 
genetically obese ob/ob mice, which lack Lep gene expression [14]. These findings suggest that 
leptin signaling may contribute to obesity’s pro-tumor effects on TNBC. Our findings showed that 
silencing the expression of the leptin receptor gene Lepr in E-Wnt mammary tumor cells increased 
the effectiveness of docetaxel treatment in DIO mice. Since other researchers have established that 
elevated systemic leptin levels and tumor Lep and Lepr expression are associated with worse breast 
cancer prognosis [15-18], it is highly probable that leptin signaling is a key contributor to obesity-
associated chemotherapy resistance in TNBC via TIC enrichment.  
For the in vitro part of the study, the relationship between TIC-enrichment and leptin was 
determined by assessment of mammosphere formation following leptin treatment. In a previous 
study from our laboratory [20], and here in Figure 8, the obesity micro-environment was modeled 
in vitro using serum collected from DIO and control mice, which allowed for other cytokines 
besides leptin to exert an effect. However, this technique could not be used for the mammosphere 
assays because mammosphere formation is inhibited by serum exposure. Consequently, there may 
be other contributing factors to obesity-induced mammosphere formation that also need to be 
explored. Furthermore, we are not able to conclude that the observed effects will apply to all forms 
of TNBC because TNBC is a heterogenous disease that encompasses multiple distinct molecular 
subtypes.  
While the goal of this study was to broadly characterize the impact of leptin signaling on 
TIC-related phenotypes and chemotherapy resistance, we did not attempt to distinguish the exact 
molecular pathways that led to the observed downstream effects. We can only hypothesize that the 
effects are mediated by one or both of the major pathways (JAK2/STAT3 and PI3K/AKT) found 
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by others to be implicated in leptin’s pro-TIC enriching effects [21]. Therefore, future experiments 
would need to be conducted to illuminate the pathway(s) that mediates the effects we found.  
Due to the growing prevalence of obesity in not only the United States but also worldwide, 
it is important that we improve our understanding of the obesity-breast cancer link. Our data 
suggests that leptin signaling is a major mediator in obesity-associated TNBC progression by 
promoting TIC enrichment. Furthermore, our findings indicate that silencing the leptin receptor 
reduces docetaxel resistance in a murine model of TNBC which means that inhibiting downstream 
targets of leptin signaling could be a potential treatment option for obesity-associated 
chemotherapy resistance. 
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Conclusion 
Our findings suggest that leptin signaling may promote TIC enrichment in metastatic claudin-low 
breast cancer but does not upregulate leptin receptor expression in TNBC. In addition, obesity-
associated leptin signaling promotes docetaxel resistance in a model of basal-like breast cancer. 
These findings suggest that further research regarding the role of leptin-induced TIC enrichment 
in obesity-associated TNBC progression is warranted, as greater understanding of the pathways 
mediating these effects may lead to the identification of new targets for intervention. 
 
Future Directions 
Examination of the effects of obesity-associated leptin signaling on the triple-negative metastatic 
Met-M-Wnt cell line’s response to docetaxel will be further explored via additional in vitro 
experiments and a transplant animal study. In a similar design to the E-Wnt animal study, the mice 
will be fed DIO versus control diets and administered docetaxel or vehicle treatment in order to 
examine the impact of leptin signaling on tumor growth, TIC enrichment, metastasis, and taxane 
chemotherapy response. Other chemotherapy drugs besides docetaxel will be used to characterize 
the effects of leptin signaling on TNBC chemotherapy resistance. 
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